WCLC 2025 - Posters & ePosters-EP.12.32 Targeted Therapy Utilization in Patients With Stage IV Non-Small Cell Lung Cancer Harboring Actionable Mutations

EP.12.32 Targeted Therapy Utilization in Patients With Stage IV Non-Small Cell Lung Cancer Harboring Actionable Mutations

Back to course

Pdf Summary

This study evaluates the real-world utilization of targeted therapies in U.S. oncology practices among patients diagnosed with stage IV non-small cell lung cancer (NSCLC) harboring actionable genetic mutations, between January 1, 2022, and December 31, 2024. The targeted mutations studied include EGFR (exon 19 deletion and L858R), ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK1/2/3, KRAS G12C, and ERBB2. NRG1 was recently added by NCCN guidelines but was not analyzed here.<br /><br />Patients included were adults with newly diagnosed stage IV NSCLC confirmed via manual chart review who started first- or second-line targeted therapies consistent with NCCN version 7.2025 guidelines.<br /><br />Findings show that targeted therapy utilization varies significantly by mutation type. EGFR-mutated patients had the highest targeted therapy use (approximately 90%), followed by ALK (73%), with moderate use among ROS1 and RET mutations (60%). Utilization declined among those with BRAF V600E, MET exon 14 skipping, and NTRK mutations, where only about 60% received appropriate targeted treatments. ERBB2 and NTRK-mutated patients had lower rates, under 50%.<br /><br />Histology influenced treatment receipt: 71% of patients with adenocarcinoma received targeted therapy, compared to only 36% of those with squamous cell carcinoma.<br /><br />The study concludes that despite NCCN recommendations, not all patients with actionable mutations receive targeted therapies. Contributing factors to underutilization, especially in squamous histology and certain rare mutations, require further investigation to improve treatment equity and outcomes in stage IV NSCLC.

Asset Subtitle

Edgardo S. Santos

Meta Tag

Speaker Edgardo S. Santos

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

stage IV non-small cell lung cancer

NSCLC

targeted therapies

EGFR mutations

ALK mutations

ROS1 mutations

BRAF V600E

MET exon 14 skipping

RET mutations

treatment utilization